Kate E Dibble, Ph.D.

Instructor of Medicine at @DanaFarber @harvardmed @DFCI_BreastOnc. Breast cancer survivorship, PROs, and supportive care. Alumna of @JohnsHopkinsSPH @UConn

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

#ASCO26 Poster Session | Poster #117 | Long-term safety outcomes of pregnancy among young #BreastCancer survivors: Results from a prospective, multicenter cohort study. #AYA @KimiaSorouriMD @AnnPartridgeMD @ShoshRosenberg @DrKateDibble

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

Tune in tomorrow for an update on the efficacy of YES, an mHealth intervention for adolescent and young adults (#AYA).
🗓️ Sunday, May 31
⏰ 8:00 - 8:06 AM CDT (9:00 - 9:06 AM EST)
📍 S403
@ShoshRosenberg @AnnPartridgeMD @DrKateDibble
@NabihahTayob #asco26 #breastcancer

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

New @JAMANetworkOpen multicenter study on Extended Endocrine Therapy and Survival for #BreastCancer Subtypes in Premenopausal Patients.
🔓https://t.co/8W5vW5kat8
@ValenzaCarmine @monicamilano84 @darioT_ @lorenzoguidimd @bianchitaM @DrKateDibble @elisabettasabet @curijoey @AnnPartridgeMD

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

Secondary outcomes from the YES trial will be presented tomorrow during Rapid Oral Session 1 at #ESMOBreast26. Tune if for an update on the efficacy of an mHealth intervention to address informational needs in adolescent and young adult (#AYA) #BreastCancerSurvivors.
🗓️ Thursday, May 7
⏰ 09:54 - 09:59 CEST (3:54 - 3:59 AM EST)
📍 Berlin Hall
@ShoshRosenberg @AnnPartridgeMD @DrKateDibble
@DrDawnHershman

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

From a #CancerSurvivorship-focused continuing medical education course to practice change implementation: Results of a provider survey
👉https://t.co/0rjV021EPF
@DrKateDibble @AnnPartridgeMD @DrN_CancerPCP @jcansurv

[Carmine Valenza @ValenzaCarmine]

📣 Now available as open access on @JCO_ASCO: our analysis on extended endocrine therapy (ET) in premenopausal pts with eBC after 5y of LHRHa.

https://t.co/7KTCL00PXG

Which are the pros and cons of extended ET in this setting? 🤔

A thread 🧵1/

@IEOufficiale @DFCI_BreastOnc

[Mirrors of Medicine @mirrorsmed]

Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor–Positive Breast Cancer: A Cohort Study

https://t.co/PIsZCQZavJ

This cohort analysis evaluated extended endocrine therapy 💊after five years of LHRH agonists in premenopausal women with node-positive, hormone receptor–positive early #BreastCancer . Among 501 patients, extended therapy significantly improved invasive and distant recurrence-free survival compared with stopping therapy.

Five-year invasive disease–free survival was 85% versus 78%. Benefits occurred without increased fractures or major cardiovascular events, supporting extended therapy as a clinically meaningful strategy for high-risk young patients after treatment.

@ValenzaCarmine
@darioT_
@PierPaoloBG
@bianchitaM
@DrKateDibble
@elisabettasabet
@curijoey
@AnnPartridgeMD

[Ann Partridge MD, MPH @AnnPartridgeMD]

So honored to work with this extraordinary group!

[Carmine Valenza @ValenzaCarmine]

Happy to be part of this incredible family!
❤️❤️
@DFCI_BreastOnc @DanaFarber
@AnnPartridgeMD @GuiNaderMarta @DrKateDibble

[Kate E Dibble, Ph.D. @DrKateDibble]

Come join our team! Clinical Research Coordinator (CRC) - Young Women's Program (#Boston, Massachusetts) #job https://t.co/2D7gbOF7bX @DFCI_BreastOnc

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

Check out this recent study from @DanaFarber's Young & Strong Program looking at engagement with programmatic electronic communications among young adults with #BreastCancer.
👉https://t.co/xot65lXy5x
@DrKateDibble @KimiaSorouriMD @aj_wiswell @AnnPartridgeMD #AYA #PatientEducation

[Kate E Dibble, Ph.D. @DrKateDibble]

New pub --> Engagement with Programmatic Electronic Communications among YAs with Breast Cancer published in @MASCC_JSCC. Using @DFCI_BreastOnc Young & Strong program e-comms, we aim to understand engagement & interest by topic offered. https://t.co/ycXOwfK4t2 @AnnPartridgeMD

[Kate E Dibble, Ph.D. @DrKateDibble]

New pub --> Associations between CAHPS scores of patient care experiences and breast cancer survival among senior female survivors: A SEER-CAHPS analysis, the last of my postdoc work! https://t.co/sl0AfV22j2

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

Congratulations to our @DFCI_BreastOnc providers who were named as #TopDoctors in @BostonMagazine's annual list!
✨Dr. Caroline Block @CBlockMD
✨Dr. Craig Bunnell @bunnell_craig
✨Dr. Harold Burstein @DrHBurstein
✨Dr. Judy Garber @judygarber5
✨Dr. Michael Hassett
✨Dr. Jennifer Ligibel
✨Dr. Nancy Lin @nlinmd
✨Dr. Filipa Lynce @filipalynce
✨Dr. Erica Mayer @elmayermd
✨Dr. Ann Partridge @AnnPartridgeMD
✨Dr. Geoffrey Shapiro @GShapiroMDPhD
✨Dr. Laura Dominici @dr_laurad
✨Dr. Tari King @tarikingmd
✨Dr. Beth Mittendorf @EMittendorfMD
✨Dr. Faina Nakhlis
✨Dr. Esther Rhei
✨Dr. Jennifer Bellon @jenniferbellon2
✨Dr. Laura Warren @lwarrenMD
✨ Dr. Stuart Schnitt @SchnittStuart

[Kate E Dibble, Ph.D. @DrKateDibble]

Miss you all!!!!

[Carmine Valenza @ValenzaCarmine]

DFCI Young Adult Research Team
What a Dream Team!! ❤️🔥

@AnnPartridgeMD @GuiNaderMarta @DFCI_BreastOnc @DrKateDibble @MeganTesch

[Guilherme Nader Marta @GuiNaderMarta]

Unveiling insights into Oncotype DX recurrence scores and their prognostic value in young patients with ER+ breast cancer diagnosed during pregnancy or postpartum

@AnnPartridgeMD
@DFCI_BreastOnc

[Kate E Dibble, Ph.D. @DrKateDibble]

New protocol pub on the YES intervention published in @BioMedCentral —> https://t.co/DEvDCJWWNL

@AnnPartridgeMD @ShoshRosenberg @DFCI_BreastOnc

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

#SABCS24 POSTER SESSION | P2-01-06 | Supportive care concerns of young women living with #MetastaticBreastCancer from an ongoing prospective virtual intervention. @DrKateDibble @ShoshRosenberg @PhilipPoorvu @drsarahsam @nlinmd @AnnPartridgeMD

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

#SABCS24 POSTER SESSION | P1-03-30 | Genomic risk score distribution and outcomes of patients with early-stage #BreastCancer diagnosed during pregnancy. @GuiNaderMarta @DrKateDibble @elmayermd @PhilipPoorvu @KathrynRuddyMD @nellage @DrEricWiner @AnnPartridgeMD

[Nancy Lin, MD @nlinmd]

Such great news for people in Massachusetts!

Proud of MSCO’s partnership with Dana-Farber and with appreciation to Gov Healey, and all of the legislative sponsors !